Funded Startups in Marseille
Disclosed round sizes in Marseille skew sharply: the largest disclosed amount is Adcytherix’s $122M Series A on 2025-10-16, which dwarfs the next-largest d…
Disclosed round sizes in Marseille skew sharply: the largest disclosed amount is Adcytherix’s $122M Series A on 2025-10-16, which dwarfs the next-largest disclosed rounds in the same view (DiogenX $30M on 2023-05-10 and Traxens $26M on 2022-02-08). At the other end, the smallest disclosed amount is Cynoia’s $130K Seed on 2025-01-10, creating a wide spread across these 27 entries.
The round dates span 2020-07-05 (MCES, Gaming) through 2025-10-16 (Adcytherix), with many entries clustering in 2023–2025. Sector-wise, Biotechnology appears repeatedly (Adcytherix 2025-10-16; Tafalgie Therapeutics 2025-09-19; Innate Pharma 2025-04-24; DIAMIDEX 2023-11-04; ImCheck Therapeutics 2022-06-13; VECT-HORUS 2020-12-01), while “Series Unknown” and “undisclosed” amounts recur in the list (5 entries labeled “Series Unknown” and multiple rows with “undisclosed” amounts, including Guepard on 2025-09-27 and Green Praxis on 2024-03-22).
Most recent rounds
27 shownRelated listings
Frequently asked
Which deal is the clear outlier by disclosed amount, and what sits next to it in magnitude?
Adcytherix’s $122M Series A (2025-10-16) is the only disclosed round above $100M in this view; the next-largest disclosed amounts are $38M (Volta Medical, 2023-01-05) and $30M (DiogenX, 2023-05-10), both far below Adcytherix.
Do these Marseille rounds cluster into a recent time window, or are they evenly distributed since 2020?
They concentrate heavily toward recent years: the list spans 2020-07-05 (MCES) to 2025-10-16 (Adcytherix), and a large share of dated rounds fall between 2022 and 2025, including multiple entries in 2025 (Adcytherix 2025-10-16; Guepard 2025-09-27; Rofim 2025-09-21; Tafalgie Therapeutics 2025-09-19).
Are any sectors over-represented compared with others in this city view?
Biotechnology shows up across multiple years (Adcytherix 2025-10-16, Tafalgie Therapeutics 2025-09-19, Innate Pharma 2025-04-24, DIAMIDEX 2023-11-04, ImCheck Therapeutics 2022-06-13, VECT-HORUS 2020-12-01), making it the most repeated sector category in the rows shown.
How complete are disclosed amounts and round classifications—are “Series Unknown” and “undisclosed” common enough to affect screening?
Yes. “Series Unknown” appears in five rows (e.g., Rofim on 2025-09-21 and Innate Pharma on 2025-04-24), and “undisclosed” amounts also recur (Guepard on 2025-09-27; Green Praxis on 2024-03-22; BuyCo on 2023-07-24; WeCashUp on 2022-09-07), so amount-based filtering will exclude some relevant deals.
Which entries closed most recently in the dataset, and what stage pattern do they suggest?
Within the newest quarter of entries shown (late Sep–mid Oct 2025), the dated rounds include Adcytherix $122M (Series A, 2025-10-16), Guepard (Pre-Seed, 2025-09-27; undisclosed amount), Rofim $12M (Venture - Series Unknown, 2025-09-21), and Tafalgie Therapeutics $14M (Series A, 2025-09-19), suggesting both early-stage and large Series A activity at the top end of disclosed funding.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.